Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients

Multiple Myeloma Clinical Trial

— CCD  

Official title:

A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01346787
• Other study ID #: IST-CAR-506
• Status: Completed
• Phase: Phase 2
• Start date: July 2011
• Est. completion date: May 31, 2023

Study information

• Verified date: September 2023
• Source: European Myeloma Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma (MM).

Description:

This protocol is a phase II multicenter, international, non-comparative, open label study designed to jointly assess the safety and the efficacy of the association Carfilzomib with Cyclophosphamide and Dexamethasone (CCd) as induction treatment and Carfilzomib alone as maintenance in newly diagnosed MM patients. Patients will be evaluated at scheduled visits in up to 4 study periods: pre-treatment, treatment, maintenance and long-term follow-up. The pre-treatment period includes screening visits, performed at study entry. After providing written informed consent to participate in the study, patients will be evaluated for study eligibility. The screening period includes the availability of inclusion criteria described above. The treatment period includes administration of Carfilzomib, Cyclophosphamide and Dexamethasone for 9 4-week courses. In order to assess the toxicity of treatment, patients will attend the study centre visits at each scheduled Carfilzomib administration. The response will be assessed after each 4-week cycle. The maintenance period includes carfilzomib alone on days 1, 2, 15, 16 at 36mg/m2. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator. It will be initiated at the end of the 9th course and will be stopped at progression or intolerance. The median expected duration of the maintenance treatment is approximately 2 years. The Long Term Follow Up periods will start after development of confirmed Progression Disease, all patients are to be followed for survival during the Long Term Follow Up period every 3 months via telephone or office visit. Approximately 15 Italian centers and foreign centers will participate to the protocol. Patients with symptomatic newly diagnosed MM whose age is ≥ 65 years or who are ineligible for autologous stem cell transplantation. Up to 53 patients will be enrolled from different centers. The duration of the treatment is approximately 9 months. This length of time is required to complete 9 courses of CCd. At the end of the first stage (19 patients), the trial will be temporarily stopped until all 19 patients complete the toxicity and efficacy evaluation (3 cycle): if there are more than 7 responses and less than 8 toxicities, a further group of 34 patients (total=53) will be enrolled. Otherwise, the trial will be definitively stopped or the DSMC will recommend testing other doses of the drugs. The maintenance period in both phases will start at the end of the 9th course and will be stopped at progression or intolerance. The median expected duration of the maintenance treatment is approximately 2 years. The duration of follow-up from relapse will be approximately 2 years. The occurrence of PD will determine the duration of TTP of each patient. The occurrence of death will determine the duration of overall survival. The first analysis to evaluate safety and efficacy is planned when the 19 patients enrolled in the first stage of the study have completed the third cycle of induction treatment. The trial will be stopped if there are < 6 responses, or > 9 toxicities or the Data Safety Monitoring Committee recommends testing other doses of the drugs; Otherwise, a further group of 34 patients (total=53) will be enrolled. The final conclusion will be negative if there are ≤ 23/53 responses, or ≥ 20/53 drug-related toxicities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: May 31, 2023
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Patient is of a legally consenting age as defined by local regulations.
• Patient is age = 65 year of age or who are ineligible for autologous stem cell transplantation.
• Patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
• Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
• Female patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
• Male patient agrees to use an acceptable method for contraception (i.e., condom or abstinence) for the duration of the study.
• Patient is a newly diagnosed MM patient.
• Patient has measurable disease, defined as follows: any quantifiable serum monoclonal protein value (generally, but not necessarily, = 0.5 g/dL of M-protein) and, where applicable, urine light-chain excretion of >200 mg/24 hours. For patients with oligo or non-secretory MM, it is required that they have measurable plasmacytoma > 2 cm as determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan) or an abnormal free light chain ratio (n.v.: 0.26-1.65). We anticipate that less than 10% of patients admitted to this study will be oligo- or non-secretory MM with free light chains only in order to maximize interpretation of benefit results.
• - Patient has a Karnofsky performance status =60%.
• Patient has a life-expectancy >3 months.
• Patient has the following laboratory values within 14 days before Baseline (day

1 of the Cycle 1, before study drug administration):

• Platelet count =50 x 109/L (=30 x 109 /L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to drug administration).
• Absolute neutrophil count (ANC) = 1 x 109/L without the use of growth factors.
• Corrected serum calcium =14 mg/dL (3.5 mmol/L)
• Alanine transaminase (ALT): = 3 x the ULN.
• Total bilirubin: = 2 x the ULN.
• Calculated or measured creatinine clearance: = 15 mL/minute

Exclusion Criteria:

• - Patients with non-secretory MM, unless serum free light chains are present and the ratio is abnormal.
• Pregnant or lactating females
• Patient has active infectious hepatitis type B or C or HIV.
• Patients with myocardial infarction or unstable angina = 4 months or other clinically significant heart disease (e.g., CHF NY Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
• Peripheral neuropathy > CTCAE grade 2 and = grade 2 painful peripheral neuropathy (with the difference being in the exclusion of patients with Grade 2 painful PN).
• Known history of allergy to Capsidol (a cyclodextrin derivative used to solubilize carfilzomib)
• Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.
• Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to baseline;
• Patient has any other clinically significant illness that would, in the investigator's opinion, increase the patient's risk for toxicity.
• Patients with a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix or breast, or localized prostate cancer of Gleason score <7 with a stable PSA)

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study

Locations

Country	Name	City	State
Italy	azienda ospedaliero-universitaria umberto I Clinica di Ematologia	Ancona
Italy	Policlinico S. Orsola Istituto di Ematologia e Oncologia Medica	Bologna
Italy	Ospedale Ferrarotto_Reparto di Ematologia	Catania
Italy	Az.Osp. Di Careggi_Dh ematologia	Firenze
Italy	Istituto Nazionale per lo Studio e la Cura dei Tumori_UO Ematologia_Trapianto di Midollo Osseo Allogenico	Milano
Italy	Divisione di Ematologia Dipartimento di Medicina Clinica e Sperimentale Università Amedeo Avogadro	Novara
Italy	IRCCS CROB UOC di Ematologia e trapianto cellule staminali Ospedale Oncologico Regionale	Rionero In Vulture	PZ
Italy	Cattedra di ematologia Università La Sapienza	Roma
Italy	Divisione di Ematologia Ospedale S. Eugenio	Roma
Italy	S.C.di Oncoematologia, Azienda Ospedaliera S. Maria di Terni	Terni
Italy	SC Ematologia - A.O.U. Città della Salute e della Scienza di Torino	Torino
Italy	SSD CLINICAL TRIAL IN ONCOEMATOLOGIA E MIELOMA MULTIPLO - A.O.U. Città della Salute e della Scienza di Torino	Torino
Netherlands	Erasmus MC	Rotterdam

Sponsors (2)

Lead Sponsor	Collaborator
European Myeloma Network	Fondazione EMN Italy Onlus

Countries where clinical trial is conducted

Italy,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toxicity: Assessment of adverse events will be performed at the end of third cycle according to the National Cancer Institute Common Terminology Criteria of Adverse Events (CTCAE version 4.0)	Toxicity is defined as the first occurrence of a grade 4 hematologic drug-related toxicity excluding anemia, (grade 4 neutropenia must last longer than 3 days and grade 4 thrombocytopenia must last longer than 7 days in order to be considered a toxicity) with the exception of (grade 4 neutropenia > 3 days , or grade 4 thrombocytopenia >7 days duration) or grade 3 non-hematologic drug-related toxicity.	4 years
Primary	Efficacy will be assessed by considering partial response (PR) following the proposed regimen. Assessment of Partial Response rate will be performed at the end of third cycle according to the criteria of the International Myeloma Working Group.		4 years
Secondary	Response rate		4 years
Secondary	Duration of Progression Free Survival		4 years
Secondary	Time to progression (TTP)		4 years
Secondary	Duration of Response (DOR)		4 years
Secondary	Duration of Overall Survival		4 years
Secondary	Time to next therapy		4 years
Secondary	Progressio Free Survival	Relation between responses and Progression Free Survival, in responding and non-responding patients.	4 years
Secondary	ß2-microglobulin as prognostic factors	Subgroups analysis on prognostic factors	4 years
Secondary	peripheral neuropathy	Rates of peripheral neuropathy, according to the National Cancer Institute Common Toxicity Criteria (version 4.0)	4 years
Secondary	Progression Free Survival	Effect on Progression Free Survival of maintenance with low dose of Carfilzomib (days 1 and 2 every other week)	4 years
Secondary	C reactive protein as prognostic factors	Subgroups analysis on prognostic factors	4 years
Secondary	cytogenetics as prognostic factors	Subgroups analysis on prognostic factors	4 years
Secondary	microRNA	Subgroups analysis on prognostic factors	4 years
Secondary	gene expression profile	Subgroups analysis on prognostic factors	4 years
Secondary	Overall Survival	Effect on Overall Survival of maintenance with low dose of Carfilzomib (days 1 and 2 every other week)	4 years